How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data

Simply Wall St.04-13

KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627457540?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-13 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627457540","market":"hk","top_or_hot":-1,"title":"How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data","media":"Simply Wall St.","content":"<div>\n<p>KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/how-investors-may-respond-to-kalvista-pharmaceuticals-kalv-e\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-13 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/how-investors-may-respond-to-kalvista-pharmaceuticals-kalv-e><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/how-investors-may-respond-to-kalvista-pharmaceuticals-kalv-e\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/how-investors-may-respond-to-kalvista-pharmaceuticals-kalv-e","article_id":"2627457540","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/how-investors-may-respond-to-kalvista-pharmaceuticals-kalv-e","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627457540","pubTimestamp":1776089864,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks in children aged 2–11, with no serious or treatment-related adverse events.\nThe trial, now the largest pediatric hereditary angioedema study and completed enrollment a year early, highlights strong clinical interest in a first-in-class oral option for a population currently limited to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技","ISBC":"投资者银行","BK4211":"区域性银行"},"translate_title":"投资者对KalVista Pharmaceuticals(KALV)早期KONFIDENT-KID完成和积极的EKTERLY数据有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":1.5,"ISBC":1.5},"content_text":"KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks in children aged 2–11, with no serious or treatment-related adverse events. The trial, now the largest pediatric hereditary angioedema study and completed enrollment a year early, highlights strong clinical interest in a first-in-class oral option for a population currently limited to burdensome intravenous on-demand therapy. We’ll now examine how KONFIDENT-KID’s early completion and supportive interim data might influence KalVista’s investment narrative around EKTERLY’s growth. Outshine the giants: these 21 early-stage AI stocks could fund your retirement.AdvertisementKalVista Pharmaceuticals Investment Narrative RecapTo own KalVista, you need to believe EKTERLY can become a core oral treatment across hereditary angioedema, broad enough to eventually support profitability despite today’s losses and high commercialization spend. The KONFIDENT KID interim data support EKTERLY’s clinical profile and strengthen the near term pediatric NDA catalyst, while also underscoring the key risk that broader, lower burden use could lead to less frequent refills and more normal attack patterns than early high burden adopters. Among recent announcements, the earlier FDA approval and launches of EKTERLY for patients aged 12 and older in the US and Europe are most relevant, because they establish the commercial and payer groundwork that any pediatric label expansion would enter into. Together with KONFIDENT S data in adults and adolescents, this creates a more complete backdrop for assessing how pediatric results could affect long term utilization, refill behavior and the company’s path toward earnings leverage. Yet, even as pediatric data look encouraging, tighter future payer policies and a reset in refill volumes remain risks investors should be aware of... Read the full narrative on KalVista Pharmaceuticals (it's free!)KalVista Pharmaceuticals' narrative projects $297.2 million revenue and $10.7 million earnings by 2029. This requires 492.9% yearly revenue growth and a $213.8 million earnings increase from $-203.1 million today.Uncover how KalVista Pharmaceuticals' forecasts yield a $31.00 fair value, a 60% upside to its current price.Exploring Other PerspectivesKALV 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming revenue could reach about US$750 million by 2028 and earnings turn positive, which is much more aggressive than consensus and highlights how views on EKTERLY’s long term adoption, especially if pediatric use proves broader or more limited than expected, can differ sharply among investors.Explore 6 other fair value estimates on KalVista Pharmaceuticals - why the stock might be worth less than half the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your KalVista Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free KalVista Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate KalVista Pharmaceuticals' overall financial health at a glance.Ready For A Different Approach?Opportunities like this don't last. These are today's most promising picks. Check them out now:We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if KalVista Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627457540","isCrawlerRequest":true}